Dina Kandil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dina Kandil has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Manal Fouad Elshamaa
Department of Pediatrics, National Research Centre, Cairo, Egypt
6 shared publications - Amal Saad-Hussein
National Research Centre
5 shared publications - Hebatallah Farouk
Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
5 shared publications - Eman A. Elghoroury
Clinical & Chemical Pathology Department, National Research Centre, Cairo, Egypt
4 shared publications - Solaf Ahmed Kamel
Clinical & Chemical Pathology Department, National Research Centre, Cairo, Egypt
4 shared publications - Ahmed Heiba
Internal Medicine Department, National Research Centre, Cairo, Egypt
3 shared publications
Latest Publications
- Open Access
- 1 July 2018
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 19 (3) , 191-195
Association of variable number tandem repeats polymorphism in the IL-4 gene with end-stage renal disease in children
- 1 July 2018
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 19 (3) , 191-195
Open AccessAssociation of variable number tandem repeats polymorphism in the IL-4 gene with end-stage renal disease in children
- Open Access
- 1 July 2018
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 19 (3) , 179-183
Impact of cell death pathway genes Fas 21377AA and FasL 2844CC polymorphisms on the risk of developing non-small cell lung cancer
- 1 July 2018
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 19 (3) , 179-183
Open AccessImpact of cell death pathway genes Fas 21377AA and FasL 2844CC polymorphisms on the risk of developing non-small cell lung cancer
- Open Access
- 1 June 2018
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 16 (1) , 47-51
Impact of Apo E gene polymorphism on HCV therapy related outcome in a cohort of HCV Egyptian patients
- 1 June 2018
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 16 (1) , 47-51
Open AccessImpact of Apo E gene polymorphism on HCV therapy related outcome in a cohort of HCV Egyptian patients
- Open Access
- 1 January 2017
- Published by Open Science Publishers LLP in Journal of Applied Pharmaceutical Science
- Vol. 7 (9) , 052-057
Expression of microRNAs-21 and-223 in hepatocellular carcinoma in hepatitis C virus infected Egyptian population
Background: The prognosis of hepatocellular carcinoma (HCC) in Egypt is poor due to high prevalence of hepatitis C virus (HCV). Moreover, the performance of laboratory markers for diagnosis of HCC at early stages has not been optimal. Objective: We aim to assess expression of miR -21 and miR-223 in HCC patients in the presence of HCV infection and correlate this expression with other clinical, laboratory features of HCC and other markers such as cyclase-associated protein2 (CAP2) and macrophage migration inhibitory factor (MIF). Subjects and Methods: The study included 40 cirrhotic, 40 HCC patients and 40 healthy subjects. Assessment of miRNAs was done using RT-PCR (Applied Biosystems). Results: Levels of miR-21 were higher in patient groups compared to control group and in HCC patients compared to other patients (p=0.001, 0.002 respectively). Serum levels of miR-223 showed no significant differences between cirrhotic patients and control group (p=0.2), while marked decrease in miR-223 expression levels was found in HCC patients compared to cirrhotic patients and control group (p=0.004,0.001 respectively). Conclusion: Altered serum miR-21 and -223 may play role in pathogenesis of HCC in the presence of HCV infection and might serve as a potential biomarker for detection of early HCC.
- 1 January 2017
- Published by Open Science Publishers LLP in Journal of Applied Pharmaceutical Science
- Vol. 7 (9) , 052-057
Open AccessExpression of microRNAs-21 and-223 in hepatocellular carcinoma in hepatitis C virus infected Egyptian population
Background: The prognosis of hepatocellular carcinoma (HCC) in Egypt is poor due to high prevalence of hepatitis C virus (HCV). Moreover, the performance of laboratory markers for diagnosis of HCC at early stages has not been optimal. Objective: We aim to assess expression of miR -21 and miR-223 in HCC patients in the presence of HCV infection and correlate this expression with other clinical, laboratory features of HCC and other markers such as cyclase-associated protein2 (CAP2) and macrophage migration inhibitory factor (MIF). Subjects and Methods: The study included 40 cirrhotic, 40 HCC patients and 40 healthy subjects. Assessment of miRNAs was done using RT-PCR (Applied Biosystems). Results: Levels of miR-21 were higher in patient groups compared to control group and in HCC patients compared to other patients (p=0.001, 0.002 respectively). Serum levels of miR-223 showed no significant differences between cirrhotic patients and control group (p=0.2), while marked decrease in miR-223 expression levels was found in HCC patients compared to cirrhotic patients and control group (p=0.004,0.001 respectively). Conclusion: Altered serum miR-21 and -223 may play role in pathogenesis of HCC in the presence of HCV infection and might serve as a potential biomarker for detection of early HCC.
- 1 July 2016
- Published by Elsevier in Transplant Immunology
- Vol. 37, 28-34
Fas/Fas Ligand pathways gene polymorphisms in pediatric renal allograft rejection
- 1 July 2016
- Published by Elsevier in Transplant Immunology
- Vol. 37, 28-34
Fas/Fas Ligand pathways gene polymorphisms in pediatric renal allograft rejection
- 1 March 2016
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 27 (2) , 190-198
Coagulation, thrombophilia and patency of arteriovenous fistula in children undergoing haemodialysis compared with healthy volunteers
This study aimed to assess whether markers of coagulation, fibrinolysis or thrombophilia are increased in children on haemodialysis compared with controls and whether measurement of any of these factors could help to identify patients at an increased risk of arteriovenous fistula (AVF) occlusion. Blood samples were taken from 55 children immediately before a session of haemodialysis and from 20 healthy volunteers. Thrombin–antithrombin (TAT), D-dimer, plasmin–antiplasmin (PAP) and anticardiolipin immunoglobulin G (ACA-Ig G) were measured by ELISA. Factor V Leiden mutation (G1691A) was determined by gene polymorphism [restriction fragment length polymorphism (RFLP)]. Determination of the patency of the AVF was prospectively followed up for a minimum of 4 years or until the AVF was nonfunctioning. Fifty-five patients were studied with a median follow-up of 659 days (range 30–1670 days). A significant increase was found in the levels of D-dimer, PAP and ACA-Ig G in haemodialysis patients with thrombosed and nonthrombosed native AVFs vs. controls. There was a significant difference between both chronic haemodialysis patients with thrombosed and nonthrombosed native AVF with regard to ACA-IgG levels. At 1 year follow-up, primary patency was 61.4% (27 patients). In multivariate analysis, D-dimer was inversely associated with secondary patency. Thrombophilia may predispose children with end stage renal disease to access failure. The promising finding is that in children on haemodialysis, D-dimer levels were increased and inversely correlated with secondary patency. Further evaluation is required into the possible role of D-dimer as a biomarker of AVF occlusion.
- 1 March 2016
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 27 (2) , 190-198
Coagulation, thrombophilia and patency of arteriovenous fistula in children undergoing haemodialysis compared with healthy volunteers
This study aimed to assess whether markers of coagulation, fibrinolysis or thrombophilia are increased in children on haemodialysis compared with controls and whether measurement of any of these factors could help to identify patients at an increased risk of arteriovenous fistula (AVF) occlusion. Blood samples were taken from 55 children immediately before a session of haemodialysis and from 20 healthy volunteers. Thrombin–antithrombin (TAT), D-dimer, plasmin–antiplasmin (PAP) and anticardiolipin immunoglobulin G (ACA-Ig G) were measured by ELISA. Factor V Leiden mutation (G1691A) was determined by gene polymorphism [restriction fragment length polymorphism (RFLP)]. Determination of the patency of the AVF was prospectively followed up for a minimum of 4 years or until the AVF was nonfunctioning. Fifty-five patients were studied with a median follow-up of 659 days (range 30–1670 days). A significant increase was found in the levels of D-dimer, PAP and ACA-Ig G in haemodialysis patients with thrombosed and nonthrombosed native AVFs vs. controls. There was a significant difference between both chronic haemodialysis patients with thrombosed and nonthrombosed native AVF with regard to ACA-IgG levels. At 1 year follow-up, primary patency was 61.4% (27 patients). In multivariate analysis, D-dimer was inversely associated with secondary patency. Thrombophilia may predispose children with end stage renal disease to access failure. The promising finding is that in children on haemodialysis, D-dimer levels were increased and inversely correlated with secondary patency. Further evaluation is required into the possible role of D-dimer as a biomarker of AVF occlusion.
- Open Access
- 29 April 2015
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 3 (2) , 245-249
Interactive Effects of Immunoglobulin Gamma and Human Leucocyte Antigen Genotypes on Response to Interferon Based Therapy of Hepatitis C Virus
AIM: We examined the role that immunoglobulin GM 23 and KM allotypes—genetic markers of γ and κ chains, respectively—play in response to treatment of hepatitis C virus (HCV) infection in Egyptian patients.MATERIAL AND METHODS: A total of 120 persons who had responded to HCV treatment and 125 with persistent HCV infection were genotyped for the presence of GM23 and KM determinants. HLA –C genotyping was also done.RESULTS: Association of GM 23+ and KM3 was significantly associated with non response to treatment (P < 0.0001). Individuals who lacked this GM genotype (but were positive for KM1,2 and 3) were likely to respond to treatment (P=0.045). Association of heterozygous GM23 (+/-) with KM 1,2 and 3 or KM3 alone was significantly associated with SVR (P = 0.001) and (P = 0.0001) respectively. Particular combinations of HLA and GM genotypes were associated significantly with the response to HCV treatment. The combination of HLAC2C2 and GM23+ was associated with persistence of infection (P = 0.027) while the association of HLAC2C2 and heterozygous GM23+/- was associated with SVR (P = 0.001).The association of HLAC1C1 and heterozygous GM23+/- was significantly associated with SVR (P = 0.001) and also subjects with HLA C1/C2 and heterozygous GM23+/- were likely to respond to treatment (P = 0.003) while subjects with HLA C1/C2 and GM23+ show tendency to resist to treatment (P = 0.0001).CONCLUSION: Our results didn’t support a role for KM allotypes, GM23 allotype plays a role in the persistence of HCV infection in the presence or absence of KM1,3. Interaction between certain GM and HLA-C genotypes may favor adequate response to interferon based therapies.
- 29 April 2015
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 3 (2) , 245-249
Open AccessInteractive Effects of Immunoglobulin Gamma and Human Leucocyte Antigen Genotypes on Response to Interferon Based Therapy of Hepatitis C Virus
AIM: We examined the role that immunoglobulin GM 23 and KM allotypes—genetic markers of γ and κ chains, respectively—play in response to treatment of hepatitis C virus (HCV) infection in Egyptian patients.MATERIAL AND METHODS: A total of 120 persons who had responded to HCV treatment and 125 with persistent HCV infection were genotyped for the presence of GM23 and KM determinants. HLA –C genotyping was also done.RESULTS: Association of GM 23+ and KM3 was significantly associated with non response to treatment (P < 0.0001). Individuals who lacked this GM genotype (but were positive for KM1,2 and 3) were likely to respond to treatment (P=0.045). Association of heterozygous GM23 (+/-) with KM 1,2 and 3 or KM3 alone was significantly associated with SVR (P = 0.001) and (P = 0.0001) respectively. Particular combinations of HLA and GM genotypes were associated significantly with the response to HCV treatment. The combination of HLAC2C2 and GM23+ was associated with persistence of infection (P = 0.027) while the association of HLAC2C2 and heterozygous GM23+/- was associated with SVR (P = 0.001).The association of HLAC1C1 and heterozygous GM23+/- was significantly associated with SVR (P = 0.001) and also subjects with HLA C1/C2 and heterozygous GM23+/- were likely to respond to treatment (P = 0.003) while subjects with HLA C1/C2 and GM23+ show tendency to resist to treatment (P = 0.0001).CONCLUSION: Our results didn’t support a role for KM allotypes, GM23 allotype plays a role in the persistence of HCV infection in the presence or absence of KM1,3. Interaction between certain GM and HLA-C genotypes may favor adequate response to interferon based therapies.
- Open Access
- 1 June 2014
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 12 (1) , 61-64
Impact of HLA-class I alleles on response to HCV treatment in a cohort of Egyptian patients
- 1 June 2014
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 12 (1) , 61-64
Open AccessImpact of HLA-class I alleles on response to HCV treatment in a cohort of Egyptian patients
- Open Access
- 15 March 2014
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 2 (1) , 40-45
A Study of the Interaction between Hepatitis C Virus Infection and Pulmonary Disorders: Assessment of Interferon Gamma and Alpha-1-Antitrypsin
Objectives: To study lung diseases in chronic HCV infection and vice versa and to find immunological and/or hereditary interrelating factors.Material and Methods: Study included 134 individuals, all were subjected to screening for anti-HCV antibodies by ELISA, HCV-RNA by real time PCR, pulmonary function tests, quantitative assay of interferon gamma and alpha-1- antitrypsin in serum by ELISA and genotyping of alpha-1- antitrypsin gene by Light Cycler PCR.Results: 76.5% of chronic HCV patients had abnormal PFT (P = 0.03), mainly reduced DLCO and reversible airway obstruction, and 41.6% of chest diseased patients were HCV-positive with a significant decrease in large and small airways functions. Interferon therapy improved PFT parameters. Only 33% of chronic HCV infection affected by chest abnormality responded to interferon therapy while 50% of chest free patients did. Serum IFN-γ was higher in HCV and chest patients than in control (P=0.02). All serum α1AT deficient patients had M/null genotype.Conclusions: A pathogenic role of chronic HCV infection in lung diseases is evident. Interferon treatment may reduce chest complications and improve pulmonary functions. However, chest affection may reduce the response to interferon treatment. M/null genotype of α1AT gene might play a role in chronic HCV infection and chest co-affection.
- 15 March 2014
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 2 (1) , 40-45
Open AccessA Study of the Interaction between Hepatitis C Virus Infection and Pulmonary Disorders: Assessment of Interferon Gamma and Alpha-1-Antitrypsin
Objectives: To study lung diseases in chronic HCV infection and vice versa and to find immunological and/or hereditary interrelating factors.Material and Methods: Study included 134 individuals, all were subjected to screening for anti-HCV antibodies by ELISA, HCV-RNA by real time PCR, pulmonary function tests, quantitative assay of interferon gamma and alpha-1- antitrypsin in serum by ELISA and genotyping of alpha-1- antitrypsin gene by Light Cycler PCR.Results: 76.5% of chronic HCV patients had abnormal PFT (P = 0.03), mainly reduced DLCO and reversible airway obstruction, and 41.6% of chest diseased patients were HCV-positive with a significant decrease in large and small airways functions. Interferon therapy improved PFT parameters. Only 33% of chronic HCV infection affected by chest abnormality responded to interferon therapy while 50% of chest free patients did. Serum IFN-γ was higher in HCV and chest patients than in control (P=0.02). All serum α1AT deficient patients had M/null genotype.Conclusions: A pathogenic role of chronic HCV infection in lung diseases is evident. Interferon treatment may reduce chest complications and improve pulmonary functions. However, chest affection may reduce the response to interferon treatment. M/null genotype of α1AT gene might play a role in chronic HCV infection and chest co-affection.
- 1 July 2013
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 3 (3) , 92-96
Endoglin (CD105) as a novel serum marker for hepatocellular carcinoma in Egyptian patients with chronic liver disease
- 1 July 2013
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 3 (3) , 92-96
Endoglin (CD105) as a novel serum marker for hepatocellular carcinoma in Egyptian patients with chronic liver disease